Similar Search Results

Multimarket Contact in Pharmaceutical Markets

Coronado, Francisco Javier - 2007

We analyze the effect of multimarket contact on the pricing behavior of pharmaceutical firms controlling for different levels of regulatory constraints using the IMS MIDAS database for the industry. Theoretically, under product differentiation, firms may find it profitable to allocate their...

Persistent link: https://www.econbiz.de/10012729533

Patent Protection, Creative Destruction, and Generic Entry in Pharmaceuticals : Evidence from Patent and Pricing Data

Marco, Alan - 2006

This paper merges patent citation data with data on pharmaceutical patent expirations, generic entry, and pricing to explore the effects of observable patent characteristics on off-patent and on-patent pharmaceutical pricing. Using a sample of drug patents facing generic entry in the 1990s, I...

Persistent link: https://www.econbiz.de/10012732596

Entry into New Pharmaceutical Submarkets : The Role of Submarket Concentration

Amisano, Gianni - 2014

Using a reduced form binary econometric model, we analyze the determinants of pharmaceutical companies entry decisions into new submarkets. Our sample includes data for pharmaceutical companies over the period 1987-1998 for seven countries. Estimation is done both at the aggregate level and at a...

Persistent link: https://www.econbiz.de/10012708979

Collusion in the US generic drug industry

Clark, Robert; Fabiilli, Christopher Anthony; Lasio, Laura - 2021

We study cartels that operated in the US generic drug industry, leveraging quarterly Medicaid data from 2011-2018 and a difference-in-differences approach comparing the evolution of prices of allegedly collusive drugs with a group of competitive control drugs. Our analysis highlights (i) the...

Persistent link: https://www.econbiz.de/10012670921

Dynamic effects of licensing and knowledge transfer across research stages : evidence from the pharmaceutical industry

Tian, Zhili; Siebert, Ralph - 2020

In the pharmaceutical industry, ﬁrms frequently engage in licensing agreements to overcome innovation challenges and keep up with the pace of developing new drugs. Licensing helps ﬁrms jointly develop new drugs and acquire external knowledge, which helps improve their internal drug...

Persistent link: https://www.econbiz.de/10012219514

Risk and reward in the orphan drug industry

Lo, Andrew W.; Thakor, Richard T. - 2018

Thanks to a combination of scientific advances and economic incentives, the development of therapeutics to treat rare or “orphan” diseases has grown dramatically in recent years. With the advent of FDA-approved gene therapies and the promise of gene editing, many experts believe we are at an...

Persistent link: https://www.econbiz.de/10011942396

Corporate Social Responsibility (CSR) of innovative pharmaceutical corporations : the case of BIOGEN

Witkowska, Janina - In: Comparative economic research : Central and Eastern Europe 21 (2018) 3, pp. 45-62

The aim of this paper is to discuss the common features and specificity of Corporate Social Responsibility (CSR) practices of innovative transnational corporations (TNCs) acting in the pharmaceutical industry. The innovativeness of pharmaceutical firms is understood here as their ability to make...

Persistent link: https://www.econbiz.de/10011960021

Die Rolle des Staates in der Impfstoffproduktion : technologische Restriktionen und ökonomische Ableitungen

Kirchhoff, Jasmina - 2021

Die Bundesregierung und die Europäische Kommission mussten in den letzten Wochen viel Kritik bezüglich ihrer Impfstoffbeschaffungsstrategie zur Eindämmung der Corona-Pandemie einstecken. Vor dem Hintergrund zu schleppend erscheinender Impfstofflieferungen und der zunehmenden Gefahr durch die...

Persistent link: https://www.econbiz.de/10012434819

Drugs on Tap : Managing Pharmaceuticals in Our Nation's Waters

Eckstein, Gabriel - 2018

Pharmaceuticals in the environment and public water supplies are believed to have serious impacts on human and … human health effects. Other studies more conclusively show that even minute concentrations of pharmaceuticals in the … awareness about the lack of governmental attention to the growing problem pharmaceuticals and pharmaceutical residues pose to …

Persistent link: https://www.econbiz.de/10012937158

Pioneering Advantage in Generic Drug Competition

Yu, Yu - 2014

Pharmaceutical markets experience the entry of numerous generic firms upon expiration of the brand firm's patent. In this paper, we take a close look at competition among the generic entrants during the first three years after patent expiration and examine whether there is a first mover...

Persistent link: https://www.econbiz.de/10012709667